^
    2ms
    Ambry Genetics announces a collaboration with Tempus to advance paired germline and somatic testing services for medical oncologists (Ambry Genetics Press Release)
    "Ambry Genetics...and Tempus...announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services...As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext®️ and CancerNext-Expanded®️ assays...Tempus’ xG and xG+ germline assays are a part of Tempus' extensive portfolio of oncology-focused testing solutions that maximize biomarker detection and identify actionable variants linked to targeted therapy and clinical trial options."
    Licensing / partnership
    |
    CancerNext ® • CancerNext-Expanded® • Tempus xG
    2ms
    Determining the genetic causes of bladder cancer in a family with a heritable pattern of bladder cancer (AUA 2024)
    Carriers of an FANCC pL554P mutation may be at higher risk for development of bladder cancer. However, as FANCC carrier registries have not demonstrated increased cancer incidence compared with the general population, we hypothesize that this family harbors a novel germline mutation leading to their bladder cancer propensity. Future studies are underway to perform whole-genome sequencing of germline and tumor DNA to identify additional heritable mutations that may predict bladder cancer risk.
    MSI (Microsatellite instability) • FANCC (FA Complementation Group C)
    |
    MSI-H/dMMR
    |
    CancerNext-Expanded®